Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. executive Bryan T. Vaughn reported routine equity compensation activity. As EVP, Diagnostics, he exercised restricted stock units (RSUs) into common stock on February 6 and 7, 2026, with corresponding increases in directly owned shares.
On February 6 and 9, 2026, small blocks of common stock were withheld and disposed of under code "F" at prices of $277.2 and $274.01 per share to satisfy tax withholding obligations, as noted in the footnotes. Following these transactions, he directly owned about 5,382.5702 shares of Labcorp common stock and 3,624 RSUs, which each represent the right to receive one share upon settlement.
Labcorp Holdings Inc. executive Jonathan C. Meltzer, EVP of Operations, reported multiple equity transactions in early February 2026. On February 6 and 7, 2026, a total of 530 Restricted Stock Units (RSUs) were converted to the same number of Labcorp common shares at an exercise price of $0. Some of the resulting shares were withheld to cover tax obligations.
On February 9, 2026, Meltzer sold 88 shares of common stock at $275.53 per share pursuant to a Rule 10b5-1 trading plan, and additional shares were withheld for taxes. After these transactions, he directly holds 2,787.3256 Labcorp common shares and 2,317 RSUs, each RSU representing the contingent right to receive one share of common stock.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported routine equity transactions involving restricted stock units (RSUs) and related common stock. On February 6 and 7, 2026, RSUs covering 180 and 178 shares, respectively, were converted into Labcorp common stock at an exercise price of $0 per share.
To cover tax withholding obligations tied to these vestings, 61 shares were withheld at $277.20 per share on February 6 and another 61 shares at $274.01 per share on February 9, as indicated by transaction code F. After these transactions, Kyle directly owned 3,288.4574 shares of common stock and held 1,600 RSUs, which each represent the right to receive one share of Labcorp common stock.
Labcorp Holdings Inc. executive Anita Z. Graham, EVP and CHRO, reported multiple equity transactions involving company stock and restricted stock units (RSUs). On February 6 and 7, 2026, RSUs converted into common stock (coded "M"), reflecting scheduled vesting from prior grants.
To cover tax withholding obligations, a portion of the newly delivered shares was withheld and disposed of (coded "F") at prices of $277.20 and $274.01 per share, rather than sold in an open-market trade. Each RSU represents the right to receive one share of common stock, and the filing notes grants vesting in three equal annual installments beginning on February 6, 2025 and February 7, 2024.
Following these transactions, Graham directly holds 1,213 shares of Labcorp common stock, as well as outstanding RSU balances as reflected in the derivative securities table.
Labcorp Holdings Inc. executive Amy B. Summy, EVP and Chief Marketing Officer, reported multiple equity transactions. On February 6 and 7, 2026, restricted stock units (RSUs) converted into 223 and 222 shares of common stock, respectively, at an exercise price of $0.
To cover tax withholding obligations, 92 shares of common stock at $277.2 per share on February 6 and 80 shares at $274.01 per share on February 9 were withheld and disposed of. Following these transactions, she directly beneficially owned 5,574.5 shares of common stock and continued to hold RSUs, including 1,136 and 914 units from separate awards.
Labcorp Holdings Inc. executive Megan D. Bailey reported routine equity compensation activity involving restricted stock units (RSUs) and related common stock transactions. On February 6 and 7, 2026, RSUs converted into 180, 222, and 67 shares of common stock at an exercise price of $0, reflecting vesting of prior equity awards.
To cover tax withholding obligations tied to these vestings, 72 shares were withheld at $277.20 on February 6, 2026, and 85 and 23 shares were withheld at $274.01 on February 9, 2026. After these transactions, Bailey directly held 3,883 shares of Labcorp common stock and 2,130 RSUs, which each represent a contingent right to receive one share of common stock.
Jonathan Meltzer filed a Form 144 notice to sell 91 shares of the issuer’s common stock (symbol LH) through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $25,187.89 and an approximate sale date of February 10, 2026.
The shares were acquired on February 7, 2026 via restricted stock vesting from the issuer as compensation. The filing also reports that Meltzer sold 88 common shares on February 9, 2026 for gross proceeds of $24,246.64. Common shares outstanding were 82,900,000.
A shareholder of the issuer filed a notice under Rule 144 for a planned sale of 88 shares of common stock through Fidelity Brokerage Services LLC. The filing lists an aggregate market value of 24,246.64 and shows 82,900,000 shares outstanding, with the sale expected around 02/09/2026 on the NYSE.
The 88 shares to be sold were acquired on 02/06/2026 via restricted stock vesting from the issuer as compensation, rather than a cash purchase. The signer represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Labcorp Holdings Inc. has appointed John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026, and named him to the Board’s Quality and Compliance Committee.
Dr. Sampson is vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine and previously held senior leadership roles at Duke University Health System. He is a nationally recognized neurosurgeon and physician-scientist with nearly 300 peer-reviewed publications and extensive experience in oncology, neuroscience, women’s health and personalized medicine. He will receive board compensation consistent with Labcorp’s existing director compensation program.
Labcorp Holdings Inc. amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date of its receivables facility to January 26, 2029. The facility continues to provide funding backed by accounts receivable through Labcorp Receivables LLC.
The amendment adds a committed $125 million accordion feature, allowing Labcorp Receivables to increase the facility limit from $700 million to up to $825 million at its option on or before May 29, 2026, and removes a prior 0.10% SOFR yield adjustment. Labcorp Receivables remains a separate legal entity whose creditors have first claim on its assets, with excess collections potentially remitted to Labcorp.